Modern aspects of polycystic ovary syndrome in patients with type 1 diabetes (a review)

Grigoryan, O. R.; Absatarova, Yu. S.; Андреева, Е. Н.; Мельниченко, Г. А.; Дедов, И И

doi:10.17116/repro201521227-30

Cited by 3 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the normal circulating SHBG concentrations, by decreasing the amount of bioavailable and free testosterone, might explain why the hyperandrogenic phenotype of patients with PCOS may be milder in women with type 1 diabetes compared with patients with PCOS but without diabetes despite similarly increased total testosterone concentrations (9,15,31). Also, serum testosterone concentrations may improve in patients with type 1 diabetes as they become older, similarly to what has been described in patients with PCOS but without diabetes (59).…”

Section: Discussionmentioning

confidence: 83%

“…Six addressed fertility issues and eighteen addressed menstrual cycle characteristics of type 1 diabetes but were unrelated to androgen excess ( Fig. 1 and Supplementary Data), leaving seventeen original articles dealing with androgen excess (8)(9)(10)(11)(12)(13)(14)(15)(16)(24)(25)(26)(27)(28)(29)(30)(31). Only 9 of these 17 articles contained data about the prevalence of PCOS and related traits (8,(10)(11)(12)(13)(14)(15)(16)28) and were included in the meta-analyses.…”

Section: Data Synthesis and Analysismentioning

confidence: 99%

“…The systematic review identified several articles that compared the PCOS phenotype in women with type 1 diabetes with that of women without diabetes (9,15,26,28,31). In several studies, the mean hirsutism score was lower in women with type 1 diabetes and PCOS than in their counterparts without diabetes (9,15,31), whereas no differences were found in others (16,26,28).…”

Section: Systematic Reviewmentioning

confidence: 99%

“…In several studies, the mean hirsutism score was lower in women with type 1 diabetes and PCOS than in their counterparts without diabetes (9,15,31), whereas no differences were found in others (16,26,28). The hormonal profiles of patients with PCOS, with or without type 1 diabetes, were comparable in circulating total testosterone concentrations in most studies (9,15,16,26), yet the cause of the increased free testosterone or free androgen index in patients with PCOS appears to derive from specific mechanisms in women with type 1 diabetes (15).…”

Section: Systematic Reviewmentioning

confidence: 99%

See 3 more Smart Citations

Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis

Escobar-Morreale

Roldán-Martín

2016

Diabetes Care

View full text Add to dashboard Cite

A few small studies have reported increased prevalences of polycystic ovary syndrome (PCOS) and symptoms of androgen excess in women with type 1 diabetes. PURPOSEWe performed a systematic review and meta-analysis of studies evaluating androgen excess symptoms and PCOS in women with type 1 diabetes. DATA SOURCESThe Entrez-PubMed and Scopus electronic databases were used. STUDY SELECTIONWe selected studies addressing androgen excess signs, symptoms, and disorders in girls, adolescents, and adult women with type 1 diabetes. DATA EXTRACTIONThe main outcome measures were prevalences of PCOS, hyperandrogenemia, hirsutism, menstrual dysfunction, and polycystic ovarian morphology (PCOM). DATA SYNTHESISNine primary studies involving 475 adolescent or adult women with type 1 diabetes were included. The prevalences of PCOS and associated traits in women with type 1 diabetes were 24% (95% CI 15-34) for PCOS, 25% (95% CI 17-33) for hyperandrogenemia, 25% (95% CI 16-36) for hirsutism, 24% (95% CI 17-32) for menstrual dysfunction, and 33% (95% CI 24-44) for PCOM. These figures are considerably higher than those reported earlier in the general population without diabetes. LIMITATIONSThe data collected in the original studies were heterogeneous in age, race, ethnicity, and criteria used for the diagnosis of PCOS; yet, we used a quality-effects model in the meta-analyses to overcome this limitation. CONCLUSIONSPCOS and its related traits are frequent findings in women with type 1 diabetes. PCOS may contribute to the subfertility of these women by a mechanism that does not directly depend on glycemic/metabolic control among other negative consequences for their health. Hence, screening for PCOS and androgen excess should be included in current guidelines for the management of type 1 diabetes in women.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Data Synthesis and Analysismentioning

confidence: 99%

Section: Systematic Reviewmentioning

confidence: 99%

Section: Systematic Reviewmentioning

confidence: 99%

See 2 more Smart Citations

Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis

Escobar-Morreale

Roldán-Martín

2016

Diabetes Care

View full text Add to dashboard Cite

show abstract

“…Ideas about it changed with the accumulation of knowledge about the disease development mechanisms. 11 Congenital genetic condition of PCOS contributes 79% to the total risk of the syndrome, the remaining 21% are epigenetic factors (environmental and lifestyle influences). The familial nature of the disease speaks in favour of the leading role of heredity; in girls with vague symptoms, but with a burdened family history, PCOS should be a priori assumed.…”

Section: Introductionmentioning

confidence: 99%

Morphological Changes in Ovaries in Rats with Experimental Polycystic Ovary

2020

IJFMT

View full text Add to dashboard Cite

Polycystic ovary syndrome is one of the important causes of infertility, metabolic syndrome. Complications of PCOS are a serious health hazard. The relevance of the study of morphological changes in the ovaries in rats is justified by the need to improve the treatment of PCOS. The experiment consisted in the fact that rats from the experimental group received testosterone for 7 days and were in constant artificial daylight for 60 days. As a result of histological examination of the ovaries in this group, multiple cysts, foci of fibrosis were found. Vaginal smears in rats from the experimental and control groups were collected and compared. The extracted ovaries of rats of the experimental and control groups were compared, the differences in colour according to Van Gieson X 100, haematoxylin-eosin X 40, haematoxylin-eosin X 100, B-G X 100 were analysed. Studies indicated oestrous cycle disturbance, hormonal changes in rats with experimental polycystic. The work can serve as material for further studies aimed at identifying fast and easily accessible methods for the diagnosis of metabolic syndrome predictors.

show abstract

Pathogenetic effects of folate-containing combined oral contraceptive in patients with PCOS

Андреева¹,

Absatarova²

2018

Probl. reprod.

Self Cite

View full text Add to dashboard Cite

Цель исследования-изучить влияние фолатсодержащего комбинированного орального контрацептива (КОК) на гиперандрогению, выраженность тревоги и депрессии у пациенток с синдромом поликистозных яичников (СПКЯ). Материал и методы. В исследование включены 85 женщин в возрасте 17-35 лет с СПКЯ: 1-я группа (n=30)-пациентки получали КОК, содержащий дроспиренон 3 мг, этинилэстрадиол 30 мкг, левомефолат кальция 451 мкг; 2-я группа (n=30)пациентки получали КОК, содержащий дроспиренон 3 мг, этинилэстрадиол 30 мкг; 3-я группа (n=25)-пациентки не получали КОК. Методы: анкетирование на основании Госпитальной шкалы тревоги и депрессии HADS, антропометрические измерения (индекс массы тела, окружность талии/бедер), оценка выраженности гирсутизма по шкале Ферримана-Голлвея, определение уровней тестостерона и инсулина в сыворотке крови в начале исследования и через 3 мес после начала лечения. Результаты. Через 3 мес после начала лечения у пациенток, получавших КОК, отмечено статистически значимое снижение уровня тестостерона и гирсутного числа по сравнению с исходными параметрами (p<0,05). Метаболический профиль (индекс массы тела, окружность талии/бедер и уровень инсулина) у пациенток всех групп не изменился. У всех участниц исследования до начала лечения выявлены признаки тревоги и/или депрессии. Через 3 мес после начала лечения у пациенток 1-й группы признаки тревоги и/или депрессии полностью купированы (р<0,05); у пациенток 2-й группы отмечалась статистически незначимая динамика (пограничное состояние). У пациенток 3-й группы показатели остались без изменений. Выводы. Применение фолатсодержащих КОК у пациенток с СПКЯ способствует снижению гиперандрогении, уменьшению выраженности тревоги и депрессии. Ключевые слова: фолиевая кислота, гипергомоцистеинемия, гиперандрогения, депрессивные расстройства, комбинированные оральные контрацептивы.

show abstract

Modern aspects of polycystic ovary syndrome in patients with type 1 diabetes (a review)

Cited by 3 publications

References 16 publications

Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis

Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis

Morphological Changes in Ovaries in Rats with Experimental Polycystic Ovary

Pathogenetic effects of folate-containing combined oral contraceptive in patients with PCOS

Contact Info

Product

Resources

About